Podcast 6 Dec 2024
Cracking the code of biotech valuations
Our guest on the podcast this week to discuss the biotech scene in Eastern Europe, and look at some of the challenges facing biotech companies is Adam Marťák, CEO of ambiom.
Mergers & acquisitions
- Latest Posts
News and Trends 25 Nov 2024
Evotec on the brink of acquisition: At what cost for the biotech industry?
As the signs point toward a potential Evotec acquisition, delve into what it could represent for the European biotech landscape.
News and Trends 4 Nov 2024
Top biotech deals of October 2024
Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in October 2024.
News and Trends 10 Oct 2024
Second biotech IPO boom of the year: what does it mean for the industry?
Discover why biotech is experiencing a second IPO boom in 2024 and what it means for the broader industry.
In Depth 8 Oct 2024
Top biotech deals of September 2024
There were a number of deals that stirred the biopharma industry in September. We have listed the major collaborations that took place last month.
News and Trends 12 Sep 2024
Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges
Delve into the consequences of the Inflation Reduction Act and the broader economic conditions on biotech R&D.
ADVERTISEMENT
ADVERTISEMENT
News and Trends 2 Sep 2024
Are we in an AI bubble? Biotech AI startups’ value plummet and leads to restructuration
Delve into the downturn AI is experiencing in biotech: Is the bubble bursting or is the market correcting the high expectations?
Podcast 23 Aug 2024
New German biotech spins out to develop radiotherapeutics
While it is currently owned by the Eckert & Ziegler Group, Pentixapharm will soon be spun off as a separate company. Listen to our conversation with Andreas Eckert, founder of the company
In Depth 28 Jun 2024
Going nuclear: radiopharmaceuticals funding sees surge in 2024
Emerging as a new class of drugs, radiopharmaceuticals are all the rage in cancer treatment research as biotechs nab major funding deals.
In Depth 26 Jun 2024
Biotech megadeals: Exploring the surge in $100M+ deals
Biotech and healtcare contributed to more than one out of three megadeals in 2024, find out the reasons behind it.
In Depth 24 Jun 2024
Troublesome acquisitions: when biotech M&A goes wrong
Dive deeper into the world of M&A, as we take a look at some of the most prominent failed acquisitions of the last decade.
In Depth 17 Jun 2024
Moving with the times: biopharma royalty deals on the rise
A spate of royalty deals are changing the way certain biotechs press ahead. This trend seems to be an alternative to traditional biopharma fundraising.
ADVERTISEMENT
